Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis

PLoS Medicine

Volumn 9, Issue 8, 2012, Pages

  Lv, Jicheng ^a,b   Neal, Bruce ^a   Ehteshami, Parya ^a   Ninomiya, Toshiharu ^d   Woodward, Mark ^a,c   Rodgers, Anthony ^a   Wang, Haiyan ^b   MacMahon, Stephen ^a   Turnbull, Fiona ^a   Hillis, Graham ^a   Chalmers, John ^a   Perkovic, Vlado ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; COUGHING; DIABETES MELLITUS; DIZZINESS; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOPATHY; RISK FACTOR; STROKE; SYNCOPE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY; KIDNEY DISEASES; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84865539350     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001293     Document Type: Article

References (44)

1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765-774.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913.
3. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, et al. (2003) Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 21: 707-716.
4. Law MR, Morris JK, Wald NJ, (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665.
5. Turnbull F, (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527-1535.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187.
7. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43: S1-290.
8. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, et al. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328: 634-640.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572.
10. Whitworth JA, (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983-1992.
11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, et al. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121-2158.
12. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: 3-107.
13. hypertension WgoCgftmo (2011) 2010 Chinese guidelines for the management of hypertension. Chin J Hypertens 19: 701-743.
14. Excellence NIfHaC (2011) Hypertension: clinical management of primary hypertension in adults. CG127. Available: http://guidanceniceorguk/CG127/Guidance/pdf/English.
15. Arguedas JA, Perez MI, Wright JM, (2009) Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev pp. CD004349.
16. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585.
17. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, et al. (2009) Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 374: 525-533.
18. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, et al. (2010) Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 56: 196-202.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65-94.
20. Woodward M (2005) Epidemiology: design and data analysis. 2nd edition. Boca Raton (Florida): Chapman and Hall/CRC Press.
21. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
22. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, et al. (1995) "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48: 851-859.
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703-713.
24. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762.
25. Estacio RO, Jeffers BW, Gifford N, Schrier RW, (2000) Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 Suppl 2: B54-64.
26. Schrier RW, Estacio RO, Esler A, Mehler P, (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086-1097.
27. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, et al. (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288: 2421-2431.
28. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, et al. (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884.
29. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, et al. (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142: 342-351.
30. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, et al. (2005) Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365: 939-946.
31. Estacio RO, Coll JR, Tran ZV, Schrier RW, (2006) Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 19: 1241-1248.
32. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31: 2115-2127.
33. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361: 1639-1650.
34. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, et al. (2002) Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 13: 1733-1739.
35. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, et al. (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918-929.
36. Hayashi K, Saruta T, Goto Y, Ishii M, (2010) Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine. Hypertens Res 33: 1211-1220.
37. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, et al. (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29: 1253-1269.
38. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, et al. (1995) Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 92: 2437-2445.
39. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, et al. (2005) Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170-2179.
40. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, et al. (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144: 884-893.
41. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, et al. (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27: 1360-1369.
42. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ, (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122: 290-300.
43. Law MR, Wald NJ, Morris JK, Jordan RE, (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.
44. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, et al. (2009) A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 53: 646-653.